ALX ONCOLOGY HOLDINGS INC
ALXODrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 2 past
No catalysts found.
How ALXO's past catalysts played out
Evorpacept (ALX148)
Gastric Cancer
evorpacept
Head and Neck Cancer
ALX148
Ovarian Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Evorpacept (ALX148) | Phase 3 | Gastric Cancer | - | - |
evorpacept | Phase 2 | Head and Neck Cancer | - | - |
ALX148 | Phase 2 | Ovarian Cancer | - | - |
Frequently asked questions
What is in ALX ONCOLOGY HOLDINGS INC's drug pipeline?→
CatalystAlert tracks 3 drug candidates in ALX ONCOLOGY HOLDINGS INC's (ALXO) pipeline across Phase 3, Phase 2. Its lead program is Evorpacept (ALX148) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ALX ONCOLOGY HOLDINGS INC's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for ALX ONCOLOGY HOLDINGS INC (ALXO) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ALXO biotech catalysts?→
Add ALXO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ALX ONCOLOGY HOLDINGS INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.